Rigel Pharmaceuticals
Rigel Pharmaceuticals develops novel therapies for hematologic disorders and cancer, including TAVALISSE for chronic immune thrombocytopenia and REZLIDHIA for acute myeloid leukemia. The company collaborates with several global partners and has proprietary programs focused on IRAK1/4 and RIPK1 inhibitors.
Services
Rigel Pharmaceuticals is focused on developing novel therapies for hematologic disorders and cancer. The company's services prominently include the development and commercialization of specialized medications like TAVALISSE for chronic immune thrombocytopenia (ITP) and REZLIDHIA for acute myeloid leukemia with IDH1 mutations. Rigel also engages in collaborative research and development programs with various partners across the globe to advance its proprietary drug candidates focused on inflammatory and autoimmune diseases.
Products
Rigel Pharmaceuticals' key products include TAVALISSE (fostamatinib disodium hexahydrate) and REZLIDHIA (olutasidenib) capsules. TAVALISSE is used for treating adult patients with chronic immune thrombocytopenia (ITP), while REZLIDHIA targets relapsed or refractory acute myeloid leukemia in adults with a susceptible IDH1 mutation. The company's pipeline also features molecules like R552 and R289, which are in various stages of development for treating autoimmune and inflammatory disorders. Additionally, bemcentinib, an AXL inhibitor, is notable for its progress in clinical trials.
Collaborations
Rigel Pharmaceuticals collaborates with numerous global partners including BerGenBio, Daiichi-Sankyo, Grifols, Kissei, Knight, Lilly, Medison, and Novo Nordisk. These collaborations involve exclusive licensing agreements for the commercialization and development of Rigel's therapeutics across multiple regions. Notable partnerships include Lilly for RIPK1 inhibitor programs and Medison for the commercialization of fostamatinib in Canada and Israel. Rigel also has a significant partnership with Daiichi-Sankyo focusing on MDM2 protein inhibitors for cancer treatment.
Licensing Agreements
Rigel Pharmaceuticals has entered into several exclusive license and supply agreements to expand the reach of its therapies. These include agreements with Knight for Latin America, Kissei for Japan and other East Asian countries, and Grifols for Europe, Turkey, and the Middle East. Additionally, Rigel has licensed fostamatinib to Medison for Canada and Israel. The company has also secured a worldwide research and development agreement with BerGenBio for bemcentinib and a global exclusive license with Forma Therapeutics (now Novo Nordisk) for olutasidenib.